NS Partners Ltd increased its position in Pfizer, Inc. (NYSE:PFE) by 0.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 364,201 shares of the biopharmaceutical company’s stock after buying an additional 397 shares during the period. Pfizer makes up about 1.8% of NS Partners Ltd’s investment portfolio, making the stock its 11th largest position. NS Partners Ltd’s holdings in Pfizer were worth $12,459,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in the company. Glassman Wealth Services raised its position in shares of Pfizer by 1.7% in the fourth quarter. Glassman Wealth Services now owns 9,605 shares of the biopharmaceutical company’s stock worth $312,000 after buying an additional 159 shares during the last quarter. Cheviot Value Management LLC increased its stake in Pfizer by 0.6% in the fourth quarter. Cheviot Value Management LLC now owns 212,517 shares of the biopharmaceutical company’s stock worth $6,903,000 after buying an additional 1,266 shares during the period. SRS Capital Advisors Inc. acquired a new stake in Pfizer during the fourth quarter worth $390,000. Freestone Capital Holdings LLC increased its stake in Pfizer by 12.9% in the fourth quarter. Freestone Capital Holdings LLC now owns 93,290 shares of the biopharmaceutical company’s stock worth $3,030,000 after buying an additional 10,639 shares during the period. Finally, Hampstead Capital LLP acquired a new stake in Pfizer during the fourth quarter worth $7,233,000. Institutional investors own 70.10% of the company’s stock.

Shares of Pfizer, Inc. (NYSE PFE) traded up 0.045% during mid-day trading on Friday, reaching $33.435. 4,218,309 shares of the company’s stock were exchanged. The company has a market cap of $199.53 billion, a PE ratio of 24.459 and a beta of 1.00. Pfizer, Inc. has a 52-week low of $29.83 and a 52-week high of $35.38. The company’s 50-day moving average price is $33.43 and its 200 day moving average price is $33.30.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. The company had revenue of $12.90 billion for the quarter, compared to the consensus estimate of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.11%. The firm’s quarterly revenue was down 1.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.64 EPS. On average, equities research analysts predict that Pfizer, Inc. will post $2.56 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Friday, August 4th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.83%. The ex-dividend date is Wednesday, August 2nd. Pfizer’s dividend payout ratio (DPR) is currently 94.12%.

TRADEMARK VIOLATION NOTICE: This report was reported by Daily Political and is owned by of Daily Political. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/08/11/ns-partners-ltd-boosts-stake-in-pfizer-inc-nysepfe.html.

Several equities research analysts have commented on PFE shares. Citigroup Inc. downgraded shares of Pfizer from a “neutral” rating to a “sell” rating and lowered their target price for the company from $38.00 to $31.00 in a research note on Tuesday, May 16th. BidaskClub raised shares of Pfizer from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 5th. Jefferies Group LLC set a $35.00 target price on shares of Pfizer and gave the company a “neutral” rating in a research note on Wednesday, August 2nd. BMO Capital Markets raised shares of Pfizer from a “market perform” rating to an “outperform” rating and upped their target price for the company from $33.00 to $37.00 in a research note on Wednesday, August 2nd. Finally, Barclays PLC reaffirmed a “buy” rating and issued a $38.00 target price on shares of Pfizer in a research note on Wednesday, May 3rd. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $37.77.

In other Pfizer news, CEO Ian C. Read sold 96,950 shares of the company’s stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $34.00, for a total transaction of $3,296,300.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Alexander R. Mackenzie sold 15,000 shares of the company’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $33.50, for a total transaction of $502,500.00. Following the sale, the insider now directly owns 151,474 shares in the company, valued at $5,074,379. The disclosure for this sale can be found here. 0.06% of the stock is currently owned by insiders.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.